X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
ON 01910 (rigosertib) is a small molecule that inhibits multiple cell signaling pathways that drive cancer growth while having little effect on normal cells. In contrast to many kinase inhibitors.
Lead Product(s): Rigosertib,Pembrolizumab
Therapeutic Area: Oncology Product Name: ON 01910
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2023
Details:
The collaboration will leverage Pangea Biomed’s proprietary algorithmic platform, ENLIGHT, for identifying biomarkers of response to Onconova’s proprietary investigational ON-01910 (rigosertib) with the ability to potently inhibit PLK1 to treat a range of solid cancers.
Lead Product(s): Rigosertib,Nivolumab
Therapeutic Area: Oncology Product Name: ON-01910
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Onconova Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 23, 2023
Details:
ON-01910 (rigosertib) is an investigational product candidate with a multi-faceted mechanism of action targeting proteins containing the RAS binding domain, allowing it to modulate the PI3K and PLK-1 pathways, as well as the tumor immune microenvironment.
Lead Product(s): Rigosertib
Therapeutic Area: Oncology Product Name: ON-01910
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2023
Details:
ON-01910 (rigosertib) is a small molecule that inhibits multiple cellular signaling pathways driving cancer cell growth. The studied doublet study has been generally well tolerated. Treatment-related adverse events (TRAE) have been mostly mild and manageable.
Lead Product(s): Rigosertib,Nivolumab
Therapeutic Area: Oncology Product Name: ON-01910
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
Details:
The trial continues to recruit patients as part of the expansion phase at the highest dose of oral rigosertib defined in the current protocol.
Lead Product(s): Rigosertib,Nivolumab
Therapeutic Area: Oncology Product Name: ON-01910
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2021
Details:
In open-label investigator-initiated study, 12 patients will receive either oral or intravenous rigosertib at the clinician’s discretion given the various clinical manifestations of the disease, which may dictate the need for either oral/intravenous rigosertib administration.
Lead Product(s): Rigosertib
Therapeutic Area: Genetic Disease Product Name: ON-01910
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2021
Details:
Onconova Therapeutics has submitted an application with the National Institute of Allergy and Infectious Disease (NIAID), with the goal of obtaining funding from the National Institutes of Health (NIH) to conduct human studies with rigosertib in COVID-19 disease patients.
Lead Product(s): Rigosertib
Therapeutic Area: Infections and Infectious Diseases Product Name: ON-01910
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2020
Details:
The authors found that non-clinical grade rigosertib used in in vitro studies by others contained impurities and degradation products in sufficient quantities to impact cellular function.
Lead Product(s): Rigosertib
Therapeutic Area: Oncology Product Name: ON 01910
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 23, 2020
Details:
Results coupled with preliminary data from the phase II studies, support further clinical development of oral rigosertib in combination with standard dose azacitidine with a manageable safety profile and efficacy in patients with MDS both those HMA naïve and after HMA failure.
Lead Product(s): Rigosertib,Azacitidine
Therapeutic Area: Oncology Product Name: ON-01910
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2020
Details:
The investigator-initiated trial is an open-label, dose-escalating Phase 1 study followed by a Phase 2a dose-expansion phase to study the combination of oral rigosertib and nivolumab in metastatic KRAS+ lung adenocarcinoma patients who are on standard frontline treatment.
Lead Product(s): Rigosertib,Nivolumab
Therapeutic Area: Oncology Product Name: ON-01910
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
Details:
The company announced updated aggregated baseline genomic data from HMA-failure patients screened for the INSPIRE trial were presented in an e-poster at the virtual 25th Annual EHA Congress.
Lead Product(s): Rigosertib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2020
Details:
Company has completed the planned enrollment of 360 patients in the INSPIRE trial in higher-risk (HR) MDS patients. INSPIRE is one of the largest studies ever conducted in this patient population.
Lead Product(s): Rigosertib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
